Prophylactic cranial irradiation with combined modality therapy for patients with locally advanced non-small cell lung cancer.
Central nervous system (CNS) metastasis is a significant problem for many patients with non-small cell lung cancer (NSCLC). The earlier data reported a high incidence of CNS metastasis in patients with locally advanced NSCLC who were treated with radiotherapy alone. However, poor control of both thoracic and extracranial systemic disease dominated the results of the early trials. The risk for CNS metastasis as the first site of failure remains a significant concern for patients who have completed modern combined modality therapy. With improvements in the treatment of thoracic and systemic disease, there is renewed interest in prophylactic cranial irradiation (PCI). The results from the Radiation Therapy Oncology Group (RTOG) trial of PCI to prevent CNS relapse in patients with locally advanced NSCLC are anticipated.
Cho
L Chinsoo
LC
Department of Radiation Oncology, UT Southwestern Medical Center at Dallas, Moncrief Radiation Oncology Center, Harold C. Simmons Comprehensive Cancer Center, Dallas, TX 75390, USA. lawrence.cho@utsouthwestern.edu
Dowell
Jonathan E
JE
Garwood
Dan
D
Spangler
Ann
A
Choy
Hak
H
D002289:Carcinoma, Non-Small-Cell Lung / Q000556:secondary / Q000628:therapy*; D016543:Central Nervous System Neoplasms / Q000517:prevention & control* / Q000556:secondary; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*